Skip to main content
. 2019 Dec 19;12:11305–11311. doi: 10.2147/OTT.S228301

Figure 3.

Figure 3

The change of Immunohistochemistry. (A) Jan 2016, resistant to AZD9291, indicated SCLC (IHC: NapsinA−, TTF1+, Syn+). (B) Oct 2016, lesion A after resistant to IO, indicated SCLC (IHC: NapsinA-,TTF-1+, Syn-, CD56+). (C) Oct 2016, lesion B after reistance to IO, indicated adenocarcinoma (IHC: NapsinA+,TTF-1+).